

Tze-Peng Lim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7473226/publications.pdf>

Version: 2024-02-01

25
papers

789
citations

687363

13
h-index

580821

25
g-index

26
all docs

26
docs citations

26
times ranked

1519
citing authors

#	ARTICLE	IF	CITATIONS
1	Antimicrobial Cluster Bombs: Silver Nanoclusters Packed with Daptomycin. ACS Nano, 2016, 10, 7934-7942.	14.6	304
2	In-Vitro Activity of Polymyxin B, Rifampicin, Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii in Singapore. PLoS ONE, 2011, 6, e18485.	2.5	55
3	Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B. PLoS ONE, 2011, 6, e28177.	2.5	51
4	Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations. Antimicrobial Resistance and Infection Control, 2015, 4, 2.	4.1	42
5	<i>In Vitro</i>Pharmacodynamics of Various Antibiotics in Combination against Extensively Drug-Resistant Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2015, 59, 2515-2524.	3.2	39
6	Molecular mechanisms of azole resistance in Candida bloodstream isolates. BMC Infectious Diseases, 2019, 19, 63.	2.9	34
7	Quantitative Assessment of Combination Antimicrobial Therapy against Multidrug-Resistant <i>Acinetobacter baumannii</i>. Antimicrobial Agents and Chemotherapy, 2008, 52, 2898-2904.	3.2	31
8	mcr-1 in Multidrug-Resistant blaKPC-2-Producing Clinical Enterobacteriaceae Isolates in Singapore. Antimicrobial Agents and Chemotherapy, 2016, 60, 6435-6437.	3.2	29
9	In vitro activity of various combinations of antimicrobials against carbapenem-resistant Acinetobacter species in Singapore. Journal of Antibiotics, 2009, 62, 675-679.	2.0	27
10	Carbapenem Resistance in Gram-Negative Bacteria: The Not-So-Little Problem in the Little Red Dot. Microorganisms, 2016, 4, 13.	3.6	26
11	Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections. Antimicrobial Agents and Chemotherapy, 2016, 60, 4013-4022.	3.2	24
12	Candidemia in a major regional tertiary referral hospital – epidemiology, practice patterns and outcomes. Antimicrobial Resistance and Infection Control, 2017, 6, 27.	4.1	24
13	<i>In Vitro</i>Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B. Antimicrobial Agents and Chemotherapy, 2016, 60, 5238-5246.	3.2	14
14	Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	14
15	Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections – A Cohort Study. Antibiotics, 2020, 9, 451.	3.7	14
16	From Bench-Top to Bedside: A Prospective In Vitro Antibiotic Combination Testing (iACT) Service to Guide the Selection of Rationally Optimized Antimicrobial Combinations against Extensively Drug Resistant (XDR) Gram Negative Bacteria (GNB). PLoS ONE, 2016, 11, e0158740.	2.5	13
17	Determining the Development of Persisters in Extensively Drug-Resistant Acinetobacter baumannii upon Exposure to Polymyxin B-Based Antibiotic Combinations Using Flow Cytometry. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
18	Rapid Antibiotic Combination Testing for Carbapenem-Resistant Gram-Negative Bacteria within Six Hours Using ATP Bioluminescence. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	10

#	ARTICLE	IF	CITATIONS
19	In vitro Pharmacodynamics and PK/PD in Animals. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1145, 105-116.	1.6	7
20	Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1591-1596.	2.7	6
21	Performance of Population Pharmacokinetic Models in Predicting Polymyxin B Exposures. <i>Microorganisms</i> , 2020, 8, 1814.	3.6	4
22	<i>In Vitro</i> Pharmacodynamics of Fosfomycin against Carbapenem-Resistant <i>Enterobacter cloacae</i> and <i>Klebsiella aerogenes</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	3
23	Intravenous ceftaroline 200mg administered every 8h is safe and adequate for methicillin-resistant <i>Staphylococcus aureus</i> bloodstream infections in end-stage renal failure patients on haemodialysis: a case study. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 720-721.	2.5	2
24	Quantification of Fosfomycin in Combination with Nine Antibiotics in Human Plasma and Cation-Adjusted Mueller-Hinton II Broth via LCMS. <i>Antibiotics</i> , 2022, 11, 54.	3.7	2
25	Elimination of Extracellular Adenosine Triphosphate for the Rapid Prediction of Quantitative Plate Counts in 24 h Time-Kill Studies against Carbapenem-Resistant Gram-Negative Bacteria. <i>Microorganisms</i> , 2020, 8, 1489.	3.6	1